Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,123.00 -1.21 (-0.11%)
Official Closing Price Updated: 7:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy. ↗
During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it. 
Via The Motley Fool
Topics ETFs
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
This company aims to serve a market heading toward $100 billion. 
Via The Motley Fool
News headline image
CVS Health Eyes Margin Recovery, Cash Flow as 2027 Headwinds Loom ↗
CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on... 
Via MarketBeat
Topics Earnings
News headline image
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 ↗
Hint: It's a good idea to buy the stock today. 
Via The Motley Fool
News headline image
If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗
Low-cost index funds can be a ticket to prosperity for everyday investors. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
News headline image
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back ↗
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation. 
Via Benzinga
Topics ETFs
News headline image
Why Is Eli Lilly Stock Falling Tuesday? ↗
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed. 
Via Benzinga
News headline image
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday. 
Via Investor's Business Daily
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
News headline image
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes. 
Via MarketBeat
Topics Artificial Intelligence Bonds
News headline image
Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock ↗
Is this big pharma stock still a buy for investors who aren't billionaires? 
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company. 
Via The Motley Fool
News headline image
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years ↗
Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings. 
Via The Motley Fool
News headline image
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. ↗
Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues. 
Via The Motley Fool
News headline image
MarketBeat Week in Review – 08/31 - 09/04 ↗
Stocks pulled back after a strong jobs report stoked rate-hike concerns. MarketBeat writers recap earnings-season themes, covering AI, cybersecurity, retail, energy, and dividend stocks. 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus. 
Via MarketBeat
News headline image
If a Bear Market Is Coming, Is VOO or VTI the Safer Investment? ↗
You can't go wrong with either, but one has a key difference that gives it the edge. 
Via The Motley Fool
Topics ETFs
News headline image
2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗
You might regret ignoring these companies at current levels. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Great News for Eli Lilly Stock Investors ↗
There is no end in sight for the company's incredible momentum. 
Via The Motley Fool
News headline image
Eli Lilly Just Announced a Major Acquisition. Here's What It Means. ↗
The drug giant added to its immunotherapy portfolio. 
Via The Motley Fool
News headline image
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity ↗
Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the broader health care sector. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.